RIDR-PI-103
RIDR-PI-103 is a reactive oxygen species (ROS) -induced agent release proagent with a self-cyclizing moiety linked to a pan-PI3K inhibitor (PI-103) . Doxorubicin and RIDR-PI-103 shows a synergistic effect in MDA-MB-361 and MDA-MB-231 cells to inhibit cancer cell proliferation[1][2].
Product Specifications
CAS Number
2581114-71-6
UNSPSC
12352005
Target
Reactive Oxygen Species (ROS)
Type
Reference compound
Related Pathways
Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/ridr-pi-103.html
Purity
98.02
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(CN)NC1=CC(N)=CC=C1OC2=CC=CC(C3=NC4=C(C(N5CCOCC5)=N3)OC6=NC=CC=C64)=C2
Molecular Formula
C27H25N7O4
Molecular Weight
511.53
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (rNGFR/1965), CF647 conjugate, 0.1mg/mL
Eotaxin 2 (CCL24) Human Gene Knockout Kit (CRISPR)
